renal transplantation -friday_prof_ayman refaei
TRANSCRIPT
![Page 1: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/1.jpg)
![Page 2: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/2.jpg)
WELCOME
![Page 3: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/3.jpg)
RENAL TRANSPLANTATION: AN OVERVIEW
Ayman Refaie,MD
Chief, Nephrology & transplantation Unit
Urology and Nephrology Center
University of Mansoura
![Page 4: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/4.jpg)
Agenda
• Benefits of transplantation
• Patient and donor selection
• The transplant anatomy
• Immunosuppressive medications
• Common post-transplant complications
• Mansoura Experience
![Page 5: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/5.jpg)
Renal Transplantation
• Kidney transplantation is the most effective therapy for end-
stage renal disease.
• The transplanted organ can come from either a live donor or
deceased donor.
• Most deceased donor organs come from brain dead donors.
• Non-standard criteria donors:
– Expanded criteria donors (ECD).
– Donation after cardiac death (DCD).
![Page 6: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/6.jpg)
Benefits of Transplantation
• Life expectancy
• Cardiovascular benefits
• Quality of life
• Socioeconomic benefits
![Page 7: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/7.jpg)
Life Expectancy
Ojo, J Am Soc Neph, 2001;12:589
![Page 8: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/8.jpg)
Life Expectancy
![Page 9: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/9.jpg)
Cardiovascular Benefits
Foley, Am J Kidney Dis, 1998;32(S1):8Slide courtesy of Dr. Robert Gaston
![Page 10: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/10.jpg)
Quality of Life
• Numerous studies have detailed improved quality of life.
• Life satisfaction, physical and emotional well-being and
ability to return to work higher in transplant recipients.
• Uremic complications more fully reversed.
• Fertility returns.
![Page 11: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/11.jpg)
A healthy child born to a female transplant recipient, 3 years after a successful engraftment.
![Page 12: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/12.jpg)
Socioeconomic Benefits
• Increased rates of return to work.
• Mean cumulative costs of dialysis and transplantation
are equal for first year, then lower for transplantation.
![Page 13: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/13.jpg)
Patient survival after kidney transplantation VS
hemodialysis
• Annual mortality rates for patients under dialysis range
from 21%-25%, but <8% with cadaveric and <4% with
living-related transplant recepients.
• The benefit of transplantation is most notable in young
people and in those with diabetes mellitus.
Projected years of life for patients 20-39 years old:
Dialysis Transplant
Non diabetic 20 31 years
Diabetic 8 25years
![Page 14: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/14.jpg)
Patients selection for kidney transplantation
All patients with ESRD are candidates for KT unless
contraindicated
![Page 15: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/15.jpg)
Contraindications to renal transplantation
- ABO incompatibility.
- Cystoxic antibodies against HLA antigens of donor.
- Recent or metastatic malignancy.
- Active infection.
- Severe extrarenal disease (cardiac, pulmonary, hepatic).
- Active vasculitis or glomeulonephritis.
- Noncompliance.
- Psychiatric illness including alcoholism and drug addiction.
- Primary oxalosis.
![Page 16: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/16.jpg)
Recipient Selection
• General medical condition.
• Cardiovascular screening.
• Age-appropriate routine cancer screening (pap smear,
mammography, colonoscopy, PSA).
• Infection (HIV, Hepatitis, TB).
• Presence of preformed antibody (PRA).
– Pregnancy, prior transplant, blood transfusion
• Psychosocial evaluation, including compliance.
![Page 17: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/17.jpg)
The kidney donor
Living
- Living related.
- Living unrelated (emotionally motivated).
Cadaveric
- Heart Beating
- Non-beating heart.
![Page 18: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/18.jpg)
Criteria for living donor selection
- Highly motivated.
- Excellent medical condition with normal renal function.
- ABO blood group-compatible.
- HLA-identical or haploidentical with negative cross-
match.
![Page 19: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/19.jpg)
Matching between Recipient and Donor
A- Compatible ABO blood group
B- Cross matching
C- Tissue typing
• Determined by 6 antigens located on cell surface encoded for by the HLA gen located on the short arm of chromosome 6.
• Class I antigens (HLA-A and HLA-B) are expressed on the surface of most nucleated cells.
• Class II antigen (HLA-DR) are expressed on surface of APC and activated lymphocytes.
![Page 20: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/20.jpg)
Effect of HLA Matching on The Graft Outcome
![Page 21: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/21.jpg)
Whether there is a medical condition that will put donor
at increased risk for complications for general anesthesia
or surgery.
Whether the removal of one kidney will increase the
donor’s risk for developing renal insufficiency.
Principles involved in evaluating a prospective
living kidney donor
![Page 22: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/22.jpg)
The living kidney donor:
giving life, avoiding harm
![Page 23: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/23.jpg)
Medical conditions that exclude living kidney donation
Renal parenchymal disease.
Conditions that may predispose to renal disease
History of stone disease
History of frequent UTI
Hypertension
D.M.
Conditions that increase the risks of anesthesia and surgery.
Recent malignancy.
![Page 24: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/24.jpg)
• Is it an easy task?
Potential living donors should undergo a rigorous screening
procedure to ensure the best functional outcome for recipients with
no or minimal morbidity for donors.
![Page 25: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/25.jpg)
Between 1992 and 2001, 1,661 ABO compatible potential living donors were evaluated
clinically as well as by laboratory and imaging studies.
814 potential donors (49%) were excluded.
![Page 26: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/26.jpg)
26
![Page 27: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/27.jpg)
Does donation of a kidney pose a long-term risk
for the donor?
Following nephrectomy, compensatory hypertrophy and
increase in GFR occur in the remaining kidney.
Slight risk of poteinuria and hypertension.
Meta-analysis of data from donors followed for >20y
confirmed safety of kidney donation.
![Page 28: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/28.jpg)
• Over the last decade.
• Mansoura Post donation Clinic.
• Recipient (hand in hand) with his/her related donor
• Evaluation:
Clinical: BP, BMI
Lab: urinalysis, S. Cr, Cr Clearance, etc…..
U/s for the remaining kidney
• Medications: provided when needed.
28
![Page 29: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/29.jpg)
Anatomy of Renal Transplantation
![Page 30: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/30.jpg)
An adult donor kidney transplanted to a pediatric recipient
![Page 31: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/31.jpg)
Principles of immunosuppressive treatment
1- Immunosuppressive therapy is required indefinitely.
2- The benefits of a successful transplant outweigh the risks of
chronic immunosuppression.
3- Large doses of immunosuppressant drugs are used in the
early transplant period.
4- Multidrug regimens are generally employed.
![Page 32: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/32.jpg)
Induction immunosuppressive therapy
• Induction therapy
• Maintenance therapy
• Treatment of rejection
![Page 33: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/33.jpg)
Induction Therapy: Why?
• To decrease rejection rate.
• To decrease graft loss.
• To lower DGF.
• To avoid or withdraw steroids.
• To avoid or delay CNIs.
• To transplant high risk patients.
• To induce tolerance……
![Page 34: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/34.jpg)
Induction Therapy: Agents
Depleting Non-Depleting
![Page 35: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/35.jpg)
Class Examples
Glucocoriticoids
Immunophilin-binding agents Calcineurin inhibitors
CyclosporineTacrolimus (FK506)
Calcinurin-independent agentsSirolimus (rapamycin)
Antimetabolites Purine inhibitors: nonselectiveAzathioprine (Imuran)
Purine inhibitors:lymphocyte selectiveMycophenolate mofetil (Cellcept)
Classes of Maintenance Immunosuppressive Drugs
![Page 36: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/36.jpg)
• Treatment of Rejection:– Corticosteroids
– Anti-thymocyte globulin
– Intravenous Immunoglobulin (IVIG)
– Rituximab
– Plasmapheresis
Immunosuppressive Medications
![Page 37: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/37.jpg)
Immunosuppressive Medications
![Page 38: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/38.jpg)
Immunosuppressive Medications
Slide courtesy of Dr. Meier-Kriesche
![Page 39: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/39.jpg)
Calcineurin Inhibitors (CNIs)
• Used for maintenance immunosuppression.
• Two agents in clinical practice:
– Cyclosporine (Sandimmune®, Neoral®)
– Tacrolimus (Prograf®).
• At present are key to maintenance immunosuppression
and a component of the majority of transplant protocols.
![Page 40: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/40.jpg)
mTOR Inhibitors
• Target site is the mammalian target of rapamycin
(mTOR), a key regulatory kinase in cell division.
• Sirolimus (Rapamune®)
Administered once daily, 24-hour trough levels
monitored.
• Everolimus (Certcan®)
Administered twice daily, 12-hour trough levels
monitored.
![Page 41: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/41.jpg)
Sirolimus: Adverse Effects
• Nephrotoxicity:
– Delays recovery from ATN.
– Potentiates cyclosporine nephrotoxicity.
– Induces proteinuria.
– Tubulotoxic.
• Impairment of wound healing.
• Dyslipidemia (increased LDL and TGs).
• Pneumonitis.
• Cytopenias and anemia.
![Page 42: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/42.jpg)
Antimetabolites
• Azathioprine (Imuran®) is a purine analogue that is
incorporated into RNA and inhibits cell replication.
• A mainstay of transplantation for 30 years, it has largely
been replaced by the below drugs.
• Mycophenolate mofetil (Cellcept®) and enteric-coated
mycophenolate sodium (Myfortic®) are prodrugs of
mycophenolic acid (MPA), an inhibitor of inosine
monophosphate dehydrogenase (IMPDH).
![Page 43: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/43.jpg)
Antimetabolites: Adverse Effects
• Azathioprine:– Bone marrow suppression.
– Hepatitis.
– Azathioprine is inactivated by xanthine oxidase, therefore should not be used in combination with allopurinol.
• MPA prodrugs:– GI toxicity: diarrhea, nausea, esophagitis.
– Leukopenia and anemia.
– Not different between formulations.
![Page 44: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/44.jpg)
Immunosuppression: Adverse Effects
![Page 45: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/45.jpg)
Common Complications of Transplantation
Early complications Surgical complications
Delayed or slow graft function
Lymphocele
Acute rejection Acute cellular rejection
Antibody-mediated rejection
Infectious complications Cytomegalovirus
BK virus
Others
Malignancy
Chronic allograft dysfunction
![Page 46: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/46.jpg)
Surgical Complications
Graft thrombosis: Caused by thrombosis of donor renal artery or vein. Usually happens in first week. Diagnosed by ultrasound with doppler studies. Almost always requires explant of kidney.
Urine leak: Elevated creatinine. May or may not have abdominal pain. Diagnose with nuclear medicine scans (DTPA or
MAG3). Surgical repair and/or relief of obstruction.
![Page 47: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/47.jpg)
Delayed Graft Function
• Need for dialysis in the first week after transplantation.
• Causes:
– ATN from prolonged cold ischemia.
– Acute rejection.
– Recurrent disease.
• Usually requires biopsy for diagnosis and management.
![Page 48: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/48.jpg)
Lymphocele
• Collection of lymph caused by leakage from iliac lymphatics.
• Presents several weeks post-operatively.
• Symptoms:
– Compression of kidney, ureter, bladder: obstructive uropathy and ARF.
– Compression of iliac vessels: unilateral lower extremity edema and DVT.
– Abdominal mass.
• Treatment is surgical.
![Page 49: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/49.jpg)
Renal Allograft Rejection
1- Hyper acute.
2- Acute.
3- Chronic.
![Page 50: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/50.jpg)
Hyperacute Rejection
Mediated by preformed antibodies that recognize HLA antigens in
donor organ.
Usually these are formed as a consequence of blood transfusion,
pregnancy, prior organ transplantation, autoimmune diseases.
Modern CM tests detect these antibodies.
Fibrinoid necrosis lead to immediate graft loss.
Delayed form may occur several days following transplantation.
Plasmapheresis and pulse steroid may be used.
![Page 51: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/51.jpg)
Hyperacute rejection.
![Page 52: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/52.jpg)
Acute Renal Allograft Rejection
Mediated by activated T-lymphocytes.
Activations of T-cells occur after recognition of graft
antigen either directly or after being processed and
presented by APC.
This usually occur during the first 6 months.
It manifest as increase in s. creatinine with or without
oliguria.
![Page 53: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/53.jpg)
Histology of acute cellular rejection
![Page 54: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/54.jpg)
Vasculitis
![Page 55: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/55.jpg)
Treatment Of Acute Rejection
1. Pulse steroids
2. ATG.
![Page 56: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/56.jpg)
Chronic rejection with tubulointerstitial lesions.
![Page 57: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/57.jpg)
Fibrointimal proliferation in renal arterioles in chronic rejection.
![Page 58: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/58.jpg)
Chronic allograft Rejection
• A- Immunologic
C4d deposits in peritubular capillaries as marker of
ongoing immune injury
• B- Non-lummunologic
• hypertension
• Hyperlipidemia
• Drug toxicity (CsA, FK)
• Ischemic injury
• Viral infection (CMV)
![Page 59: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/59.jpg)
• Manifest clinically by a slow and gradual decline in renal
function, usually more than 6 mon after transplant and typically
accompanied by moderate to heavy proteinuria.
• Histologically, characterized by glomerulo-sclerosis, interstitial
fibrosis, and obliteration of arteriolar lumina.
• Treatment is unsatisfactory.
Chronic allograft Rejection
![Page 60: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/60.jpg)
What Are The Major Causes Of Long-Term Allograft Failure ?
• Chronic rejection.
• Death with functioning graft.
![Page 61: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/61.jpg)
Cardiovascular disease.
Infection.
What Are The Most Common causes Of Death After
Kidney Transplantation?
![Page 62: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/62.jpg)
Malignancy
Recipient of organ transplants are at higher risk of developing malignancy.
May be related to impaired immune surveillance as a result of immunosuppression.
Skin cancer most common: sun protection mandatory.
Routine cancer screening.
Specific malignancies:
Kaposi sarcoma
Post-transplant lymphoproliferative disorder (PTLD)
![Page 63: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/63.jpg)
Kidney Transplantation: Mansoura Experience
![Page 64: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/64.jpg)
Sir Roy CalnePioneers in Transplantation
ATC, Philadelphia 2015
![Page 65: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/65.jpg)
![Page 66: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/66.jpg)
1967 consecutive living donor renal transplants
Between March 1976 and March 2008
Various variables that may have an impact on patients and/or graft survival
were studied in two steps.
Initially, a univariate analysis was carried out. Thereafter, significant
variables were embedded in a stepwise regression analysis.
![Page 67: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/67.jpg)
Five variables were identified as factors with an independent impact
on graft survival:
Donor’s age
![Page 68: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/68.jpg)
![Page 69: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/69.jpg)
Five variables were identified as factors with an independent impact
on graft survival:
Donor’s age
Genetic considerations
![Page 70: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/70.jpg)
![Page 71: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/71.jpg)
Five variables were identified as factors with an independent impact
on graft survival:
Donor’s age
Genetic considerations
Type of primary immunosuppression
![Page 72: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/72.jpg)
![Page 73: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/73.jpg)
Five variables were identified as factors with an independent impact
on graft survival:
Donor’s age
Genetic considerations
Type of primary immunosuppression
Number of acute rejection episodes
![Page 74: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/74.jpg)
![Page 75: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/75.jpg)
Five variables were identified as factors with an independent impact
on graft survival:
Donor’s age
Genetic considerations
Type of primary immunosuppression
Number of acute rejection episodes
Total steroid dose during the first 3 months after transplantation.
![Page 76: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/76.jpg)
![Page 77: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/77.jpg)
Five variables were identified as factors with an independent impact
on graft survival:
Donor’s age
Genetic considerations
Type of primary immunosuppression
Number of acute rejection episodes
Total steroid dose during the first 3 months after transplantation.
![Page 78: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/78.jpg)
Patient survival: 89 % at 5 years and 77 % at 10 years
Graft survival: 86 % at 5 years and 65 % at 10 years
![Page 79: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/79.jpg)
Conclusions
• Renal transplantation should be recommended as the preferred
mode of RRT for most patients with ESRD in whom surgery and
subsequent I.S. is safe and feasible
• Cr CI 50-100 ml/min.
• Anemia.
• Conception and childbearing.
• Growth in children.
• Bone metabolism.
• Work rehabilitation.
![Page 80: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/80.jpg)
Conclusions
Factors Influencing The Longevity Of Renal Allograft
• Donor age
• HLA matching
• Delayed graft function
• Ischemia time.
• Number of acute rejection episodes.
• Native kidney disease.
• Ethnicity.
![Page 81: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/81.jpg)
Risks associated with chronic Immunosuppression
• 1- Malignancy
• 2- Infection
• 3- Side effects of different drugs (steroids, CsA,
tacrolimus, MMF, …..)
Conclusions
![Page 82: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/82.jpg)
A healthy child born to a female transplant recipient, 3 years after a successful engraftment.
![Page 83: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/83.jpg)
CONGRATULATIONS
Accepted abstracts (17)
![Page 84: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/84.jpg)
CONGRATULATIONS
Accepted abstracts (5)
![Page 85: Renal transplantation -friday_prof_ayman refaei](https://reader031.vdocuments.net/reader031/viewer/2022020314/58abe7e91a28ab504e8b4a8f/html5/thumbnails/85.jpg)
Thank You